Cyp51 - cytochrome P450, family 51 Gene

Also Known as Ldm; CYPLI; P450LI; Cyp51a1; P450-14DM

Species: Mus musculus

Gene Type: protein coding
Gene ID: 13121

Summary

Predicted to enable heme binding activity and sterol 14-demethylase activity. Involved in negative regulation of amyloid-beta clearance; negative regulation of protein catabolic process; and negative regulation of protein secretion. Predicted to be located in acrosomal vesicle and endoplasmic reticulum. Is expressed in several structures, including early conceptus; genitourinary system; integumental system; jaw; and nervous system. Orthologous to human CYP51A1 (Cytochrome P450 family 51 subfamily A member 1). [provided by Alliance of Genome Resources, Apr 2022]

Cyp51 Products (1)

mRNA Protein Name
NM_020010.2 NP_064394.2 lanosterol 14-alpha demethylase

Gene Ontology

  • Biological Process
Biological Process GO Annotation Evidence References Source
involved in negative regulation of amyloid-beta clearance IMP
IMP: Inferred from mutant phenotype
20876579 MGI
involved in negative regulation of protein catabolic process IMP
IMP: Inferred from mutant phenotype
20876579 MGI
involved in negative regulation of protein secretion IMP
IMP: Inferred from mutant phenotype
20876579 MGI
EXP: Inferred from Experiment IDA: Inferred from direct assay IPI: Inferred from physical interaction IMP: Inferred from mutant phenotype IGI: Inferred from genetic interaction IEP: Inferred from expression pattern
Protein Preferred Names Protein Names

lanosterol 14-alpha demethylase

  • cytochrome P450 51A1

  • cytochrome P450, 51

  • cytochrome P450-14DM

  • cytochrome P45014DM

  • cytochrome P450LI

  • sterol 14-alpha demethylase

Related Agents

  • Approval
  • Clinical Phase
  • Pre-clinical Phase

Approval

Bioactive Molecules (1)
Cat. No. Product Name Effect
Purity Rare Diseases
HY-17643 Oteseconazole Inhibitor 99.81% Unkown

Clinical Phase

Bioactive Molecules (1)
Cat. No. Product Name Effect
Purity Phase
HY-109040 Quilseconazole Inhibitor 98.61% Phase 2

Pre-clinical Phase

Bioactive Molecules (19)
Cat. No. Product Name
Effect
Purity
Rare Diseases
HY-B0852 Tebuconazole Inhibitor 99.63% Unkown
HY-N7266 Obtusifoliol Inhibitor 99.86% Unkown
HY-117766 Opelconazole Inhibitor 98.41% Unkown
HY-122410 Dihydrolanosterol 99.72% Unkown
HY-116568 Prothioconazole Inhibitor 99.52% Unkown
HY-W1127089 Antifungal agent 136 Inhibitor 99.15% Unkown
HY-136063 Mefentrifluconazole Inhibitor 99.73% Unkown
HY-108938 SDZ285428 Inhibitor 98.00% Unkown
HY-144643 CYP51/HDAC-IN-1 Inhibitor / Unkown
HY-149617 CYP51/PD-L1-IN-4 Inhibitor / Unkown
HY-178162 CYP51-IN-27 Inhibitor / Unkown
HY-174353 CYP51-IN-22 Inhibitor / Unkown
HY-174353S CYP51-IN-23-d3 Inhibitor / Unkown
HY-170816 CYP51/Hsp90-IN-1 Inhibitor / Unkown
HY-179163 CYP51-IN-29 Inhibitor / Unkown
HY-136755 CYP51-IN-5 Inhibitor / Unkown
HY-179270 CYP51-IN-30 Inhibitor / Unkown
HY-178340 Antifungal agent 137 Inhibitor / Unkown
HY-181511 CYP51-IN-32 Inhibitor / Unkown